Broken redirects

Jump to navigation Jump to search

The following redirects link to non-existent pages:

Showing below up to 50 results in range #2,301 to #2,350.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Coronary heart disease mortality in young women makes the headline news → Special:Badtitle/NS100:Coronary heart disease mortality in young women makes the headline news
  2. Culotte is better than crush for bifurcation lesions: Results from the Nordic Stent Technique study → Special:Badtitle/NS100:Culotte is better than crush for bifurcation lesions: Results from the Nordic Stent Technique study
  3. Cyclosporine Reduces Reperfusion Injury and Infarct Size Following Acute Myocardial Infarction → Special:Badtitle/NS100:Cyclosporine Reduces Reperfusion Injury and Infarct Size Following Acute Myocardial Infarction
  4. Darapladib A Direct Lipoprotein Associated Phospholipase A2 Inhibitor Reduces Necrotic Core but not Plaque Deformability → Special:Badtitle/NS100:Darapladib A Direct Lipoprotein Associated Phospholipase A2 Inhibitor Reduces Necrotic Core but not Plaque Deformability
  5. Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure → Special:Badtitle/NS100:Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure
  6. Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction → Special:Badtitle/NS100:Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction
  7. Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control → Special:Badtitle/NS100:Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control
  8. Diagnosing Heart Failure in the Emergency Department → Special:Badtitle/NS100:Diagnosing Heart Failure in the Emergency Department
  9. Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007 → Special:Badtitle/NS100:Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007
  10. Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter → Special:Badtitle/NS100:Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter
  11. Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES) → Special:Badtitle/NS100:Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES)
  12. Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization → Special:Badtitle/NS100:Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization
  13. Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents → Special:Badtitle/NS100:Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents
  14. Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES → Special:Badtitle/NS100:Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES
  15. Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years → Special:Badtitle/NS100:Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years
  16. Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial → Special:Badtitle/NS100:Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial
  17. Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide → Special:Badtitle/NS100:Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide
  18. Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study → Special:Badtitle/NS100:Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study
  19. Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel → Special:Badtitle/NS100:Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel
  20. Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina → Special:Badtitle/NS100:Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina
  21. Emergency Medical Services Remain Underutilized in STEMI Patients → Special:Badtitle/NS100:Emergency Medical Services Remain Underutilized in STEMI Patients
  22. Eptifibatide: Result of EVA-AMI Trial Released → Special:Badtitle/NS100:Eptifibatide: Result of EVA-AMI Trial Released
  23. Eptifibatide: Results of BRIEF-PCI Trial Released → Special:Badtitle/NS100:Eptifibatide: Results of BRIEF-PCI Trial Released
  24. Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients → Special:Badtitle/NS100:Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients
  25. Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience → Special:Badtitle/NS100:Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience
  26. Excel biodegradable stents are safe and effective: Results from the CREATE trial → Special:Badtitle/NS100:Excel biodegradable stents are safe and effective: Results from the CREATE trial
  27. ExoSeal® Vascular Closure Device is safe and effective → Special:Badtitle/NS100:ExoSeal® Vascular Closure Device is safe and effective
  28. Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection → Special:Badtitle/NS100:Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection
  29. Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI → Special:Badtitle/NS100:Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI
  30. Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis → Special:Badtitle/NS100:Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis
  31. F.I.R.E. Study Misses Primary Endpoint → Special:Badtitle/NS100:F.I.R.E. Study Misses Primary Endpoint
  32. FDA Advisors Under Review for the Potential of Financial Conflict. August 8, 2007 → Special:Badtitle/NS100:FDA Advisors Under Review for the Potential of Financial Conflict
  33. FDA Panel Recommends Approval of New DES → Special:Badtitle/NS100:FDA Panel Recommends Approval of New DES
  34. FDA Requires Stronger Heart Failure Warning for Avandia and Actos → Special:Badtitle/NS100:FDA Requires Stronger Heart Failure Warning for Avandia and Actos
  35. FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study → Special:Badtitle/NS100:FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study
  36. Facilitated PCI: No Benefit in FINESSE → Special:Badtitle/NS100:Facilitated PCI: No Benefit in FINESSE
  37. Feedback regulation of catecholamines levels through an enzyme called renalase → Special:Badtitle/NS100:Feedback regulation of catecholamines levels through an enzyme called renalase
  38. Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry → Special:Badtitle/NS100:Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry
  39. Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial → Special:Badtitle/NS100:Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial
  40. Function of an obesity-associated gene defined → Special:Badtitle/NS100:Function of an obesity-associated gene defined
  41. IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes → Special:Badtitle/NS100:IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes
  42. New data on possible pro-thrombotic effects of pioglitazone → Special:Badtitle/NS100:New data on possible pro-thrombotic effects of pioglitazone
  43. Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in Lancet → Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in ''Lancet''
  44. No cardiovascular risk associated with coffee consumption after MI → Special:Badtitle/NS100:No cardiovascular risk associated with coffee consumption after MI
  45. Optimal does of aspirin following ST-elevation myocardial infarction → Special:Badtitle/NS100:Optimal does of aspirin following ST-elevation myocardial infarction
  46. PCI not Cost Effective in the Occluded Artery Trial (OAT) → Special:Badtitle/NS100:PCI not Cost Effective in the Occluded Artery Trial (OAT)
  47. RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care → Special:Badtitle/NS100:RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care
  48. STEMI patients: the untreated, reperfusion eligible. August 8, 2007 → Special:Badtitle/NS100:STEMI patients: the untreated, reperfusion eligible.
  49. Today in Medicine: Study on the Effect of Obesity on Mortality Rates Following MI → Special:Badtitle/NS100:Study on the Effect of Obesity on Mortality Rates Following MI
  50. The ARMYDA 4 Trial → Special:Badtitle/NS100:The ARMYDA 4 Trial

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://www.wikidoc.org/index.php/Special:BrokenRedirects"